Novartis' radioligand hits goal in phase 3 prostate cancer trial

A phase 3 prostate cancer clinical trial of Novaris’ targeted radioligand therapy 177Lu-PSMA-617 has met both its primary endpoints. The result tees Novartis up to seek approval for a drug it picked up in its $2.1 billion acquisition of Endocyte.